Subash C Jonnalagadda (Subash Jonnalagadda)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Venues

Biomolecules

Pharmaceuticals (Basel, Switzerland)

International journal of molecular sciences

Cancers

Rowan University

Purdue University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Rowan University Jul 01 2019

United States

Department Head :: Department of Chemistry and Biochemistry

Rowan University Sep 01 2018

United States

Professor :: Department of Chemistry and Biochemistry

Rowan University Sep 01 2013 - Aug 31 2018

United States

Associate Professor :: Department of Chemistry and Biochemistry

Rowan University Sep 01 2008 - Aug 31 2013

United States

Assistant Professor :: Department of Chemistry and Biochemistry

University of Minnesota Duluth Sep 01 2006 - Aug 01 2008

United States

Postdoctoral Research Associate :: Department of Chemistry and Biochemistry

University of Pennsylvania Sep 01 2005 - Aug 14 2006

United States

Postdoctoral Research Associate :: Department of Chemistry

Education History

Purdue University Sep 01 2000 - Aug 09 2005

United States

PHD :: Department of Chemistry

Publications

Omar S Al-Odat, Emily Nelson, Tulin Budak-Alpdogan, Subash C Jonnalagadda, Dhimant H Desai, Manoj K Pandey
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients. Cancers 16 (13) (2024)
Omar S Al-Odat, Emily Nelson, Tulin Budak-Alpdogan, Subash C Jonnalagadda, Dhimant H Desai, Manoj K Pandey
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients. Cancers 16 (13) (2024)
Weam Othman Elbezanti, Kishore B Challagundla, Subash C Jonnalagadda, Tulin Budak-Alpdogan, Manoj K Pandey
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Weam Othman Elbezanti, Kishore B Challagundla, Subash C Jonnalagadda, Tulin Budak-Alpdogan, Manoj K Pandey
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Weam Othman Elbezanti, Kishore B Challagundla, Subash C Jonnalagadda, Tulin Budak-Alpdogan, Manoj K Pandey
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Omar S Al-Odat, Daniel A Guirguis, Nicole K Schmalbach, Gabriella Yao, Tulin Budak-Alpdogan, Subash C Jonnalagadda, Manoj K Pandey
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma. International journal of molecular sciences 24 (1) (2022)
Omar S Al-Odat, Daniel A Guirguis, Nicole K Schmalbach, Gabriella Yao, Tulin Budak-Alpdogan, Subash C Jonnalagadda, Manoj K Pandey
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma. International journal of molecular sciences 24 (1) (2022)
Omar S Al-Odat, Daniel A Guirguis, Nicole K Schmalbach, Gabriella Yao, Tulin Budak-Alpdogan, Subash C Jonnalagadda, Manoj K Pandey
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma. International journal of molecular sciences 24 (1) (2022)
Mahboubeh Nabavinia, Baishali Kanjilal, Manoj K Pandey, Subash C Jonnalagadda, Robert Hesketh, Manuela M Martins-Green, Iman Noshadi
Hydrogel-Encapsulated Heterogenous Mesoporous Resin Catalyst for In Situ Anti-Cancer Agent Production under Biological Conditions. Biomolecules 12 (12) (2022)
Mahboubeh Nabavinia, Baishali Kanjilal, Manoj K Pandey, Subash C Jonnalagadda, Robert Hesketh, Manuela M Martins-Green, Iman Noshadi
Hydrogel-Encapsulated Heterogenous Mesoporous Resin Catalyst for In Situ Anti-Cancer Agent Production under Biological Conditions. Biomolecules 12 (12) (2022)
Mahboubeh Nabavinia, Baishali Kanjilal, Manoj K Pandey, Subash C Jonnalagadda, Robert Hesketh, Manuela M Martins-Green, Iman Noshadi
Hydrogel-Encapsulated Heterogenous Mesoporous Resin Catalyst for In Situ Anti-Cancer Agent Production under Biological Conditions. Biomolecules 12 (12) (2022)
Mahboubeh Nabavinia, Baishali Kanjilal, Manoj K Pandey, Subash C Jonnalagadda, Robert Hesketh, Manuela M Martins-Green, Iman Noshadi
Hydrogel-Encapsulated Heterogenous Mesoporous Resin Catalyst for In Situ Anti-Cancer Agent Production under Biological Conditions. Biomolecules 12 (12) (2022)
A K M Nawshad Hossian, Seetharama D Jois, Subash C Jonnalagadda, George Mattheolabakis
Nucleic Acid Delivery with α-Tocopherol-Polyethyleneimine-Polyethylene Glycol Nanocarrier System. International journal of nanomedicine 15 (2020)

Subash C Jonnalagadda.css-eqlu8i{font-size:small;padding-left:4px;} (Subash Jonnalagadda)

Publication Activity (10 Years)

Top Topics

Top Venues

Subash C Jonnalagadda (Subash Jonnalagadda)